Neurodevelopmental disorder Cell Models for Research

Neurodevelopmental disorders (NDDs) encompass a range of conditions including autism spectrum disorder (ASD), intellectual disability (ID), and attention-deficit/hyperactivity disorder (ADHD). According to the World Health Organization (WHO), approximately 1 in 100 children worldwide is diagnosed with ASD, and the prevalence of intellectual disability is estimated at 1-3% of the global population. These disorders often present early in life and impose significant lifelong burdens on individuals, families, and healthcare systems. The National Cancer Institute (NCI) does not track NDDs, but the National Institute of Mental Health (NIMH) reports that the economic cost of ASD in the US exceeds $268 billion annually. The clinical impact is profound, with many patients requiring lifelong support. The heterogeneity of NDDs, both clinically and genetically, underscores the need for robust research models to understand underlying mechanisms and develop targeted therapies.

NDDs are ideal for mechanistic studies due to their well-defined genetic architecture. Large-scale genomic studies, such as those from the Autism Sequencing Consortium and the Psychiatric Genomics Consortium, have identified hundreds of risk genes. Public datasets, including the SFARI Gene database and the DECIPHER database, provide curated lists of high-confidence NDD genes. Key open questions include the convergence of genetic pathways, the role of synaptic dysfunction, and the impact of environmental factors. Gene-edited cell models, particularly those derived from patient iPSCs and isogenic lines, allow researchers to dissect the functional consequences of specific mutations in a controlled genetic background, making them invaluable for studying disease mechanisms and testing therapeutic interventions.

Several key pathways are implicated in NDDs:

• • Synaptic signaling: Mutations in genes encoding synaptic proteins (e.g., SHANK3, NLGN3, NRXN1) disrupt excitatory/inhibitory balance.
• • Transcriptional regulation: Genes such as MECP2, CHD8, and FOXP2 regulate gene expression during neurodevelopment.
• • mTOR signaling: Dysregulation of the mTOR pathway (e.g., PTEN, TSC1/2) affects neuronal growth and synaptic plasticity.
• • Wnt signaling: Aberrant Wnt signaling (e.g., CTNNB1) impacts neural progenitor proliferation and differentiation.
• • Mitochondrial function: Impaired mitochondrial dynamics (e.g., SLC25A12) contribute to energy deficits in neurons.

These pathways are interconnected, and disruptions often lead to common downstream effects such as altered dendritic morphology, synaptic dysfunction, and impaired neuronal network activity.

Data from ClinVar, SFARI Gene, and DECIPHER.

Key signaling networks deregulated in NDDs include:

• • mTOR pathway: PTEN loss leads to hyperactivation of PI3K/AKT/mTOR, promoting excessive protein synthesis and altered synaptic plasticity.
• • MAPK/ERK pathway: Mutations in genes like SYNGAP1 lead to ERK overactivation, affecting synaptic function.
• • Wnt/β-catenin pathway: CHD8 mutations disrupt β-catenin signaling, impacting neural progenitor proliferation.
• • Calcium signaling: Mutations in CACNA1C and other calcium channels alter intracellular calcium dynamics, crucial for neurotransmitter release.
• • Notch signaling: Dysregulation affects neuronal differentiation and migration.

These networks are often interconnected, and their disruption contributes to the core phenotypes of NDDs.

Organoids, such as cerebral organoids, provide a 3D model that recapitulates early brain development, allowing studies of neuronal migration and network formation. They are particularly useful for modeling genetic disorders like microcephaly and ASD.

Animal models for NDDs include:

• • Genetically engineered mouse models (GEMMs): Mice with knockouts or knock-ins of NDD genes (e.g., Mecp2, Shank3, Fmr1) recapitulate behavioral and synaptic phenotypes.
• • Induced models: Pharmacological or environmental induction (e.g., valproic acid exposure) can mimic ASD-like phenotypes in rodents.
• • Patient-derived xenograft (PDX) models: Not commonly used for NDDs, but xenografts of patient-derived iPSC-derived neurons into mouse brains can study human-specific aspects.
• • Non-human primate models: CRISPR-edited monkeys (e.g., MECP2 mutants) offer closer phylogenetic relevance but are costly and ethically challenging.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations in NDD genes. For example:

• • MECP2 knockout SH-SY5Y cells: Model Rett syndrome by disrupting MECP2 function.
• • SHANK3 knockout iPSC-derived neurons: Recapitulate ASD-related synaptic deficits.
• • NRXN1 heterozygous knockout cell lines: Model haploinsufficiency seen in patients.
• • PTEN knockout neural progenitor cells: Study mTOR hyperactivation.

These models are commercially available as sequence-verified, isogenic pairs (wild-type vs. mutant) to control for genetic background. They are essential for functional validation and drug screening. Custom gene-editing services allow researchers to generate tailored models with specific mutations or reporter tags.

Gene-edited cell lines are used to validate the functional impact of NDD-associated variants. For example:

• • Knockout of CHD8 in neural progenitor cells reduces proliferation and alters differentiation, confirming its role in neurodevelopment.
• • Knock-in of a patient-specific SHANK3 mutation in iPSC-derived neurons leads to reduced synaptic density, validating the mutation's pathogenicity.
• • CRISPR screens using pooled libraries can identify genetic modifiers that rescue or exacerbate phenotypes, revealing novel therapeutic targets.

Isogenic cell line pairs (wild-type vs. mutant) are powerful tools for drug screening. For example:

• • High-throughput screening of compounds that rescue synaptic deficits in SHANK3 knockout neurons.
• • Testing mTOR inhibitors (e.g., rapamycin) in PTEN knockout cells to assess efficacy.
• • Modeling drug resistance in NDDs is less common, but gene-edited lines can be used to study how mutations affect response to existing treatments.

CRISPR-based synthetic lethality screens can identify vulnerabilities in NDD-mutant cells. For example:

• • Screening for genes that are essential only in MECP2 knockout cells may reveal novel therapeutic targets.
• • Proteomic and transcriptomic profiling of isogenic lines can identify biomarkers of disease state.
• • Reporter cell lines (e.g., GFP-tagged synaptic proteins) enable live imaging of synaptic dynamics for biomarker development.